Basic Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Nov 21, 2017; 23(43): 7678-7692
Published online Nov 21, 2017. doi: 10.3748/wjg.v23.i43.7678
Figure 7
Figure 7 LanthaScreen® TR-FRET PXR competitive binding assay was performed to determine the ability of PXR to bind to the PXR ligand binding domain and replace a fluorescent PXR ligand. SR12813, a model PXR agonist, was used as a high-affinity ligand in the PXR ligand binding domain to validate the method. The data are presented as the mean ± SD from three independent experiments (n = 3) performed in triplicate measurements. Significantly different compared to the control treatment. aP < 0.05, bP < 0.01, eP < 0.001.